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The proliferation and differentiation of cerebellar granule cell precursors (GCPs) are highly
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as a lipidmediator with a cyclic phosphate group as a regulatory factor of GCPs.While its structure
is similar to that of lysophosphatidic acid (LPA), its function is very unique. cPA is known to be
present in the cerebellum at high levels, but its function has not been fully elucidated. In this
study, we examined the role of cPA on the proliferation and differentiation of GCPs. A cell cycle
analysis of GCPs revealed that cPA reduced the number of phospho-histone H3 (Phh3)-positive
cells and bromodeoxy uridine (BrdU)-incorporated cells and increased an index of the cell cycle
exit. We next analyzed the effect of cPA on GCP differentiation using Tuj1 as a neuronal marker of
ﬁnal differentiation. The results show that cPA increased the number of Tuj1-positive cells.
Further analysis of the proliferation of GCPs showed that cPA suppressed Sonic hedgehog (Shh)-
dependent proliferation, but did not suppress insulin-like growth factor-1 (IGF-1)-dependent
proliferation. P2Y5 (LPA6), an LPA receptor, is highly expressed in GCPs. The knockdown of P2Y5
suppressed the inhibitory effect of cPA on the proliferation of GCPs, suggesting that P2Y5 is a
candidate receptor for cPA. Thus, cPA suppresses the Shh-dependent proliferation of GCPs and
promotes the differentiation of GCPs through P2Y5. These results demonstrate that cPA plays a
critical role in the development of GCPs.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).3
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Cyclic phosphatidic acid (cPA) is a lysophospholipid that has
a unique structure consisting of a cyclic phosphate at the sn-2
and sn-3 positions of its glycerol backbone (Murakami-
Murofushi et al., 1992, 2000). cPA was ﬁrst discovered in the
slime mold Physarum polycephalum (Murakami-Murofushi
et al., 1992, 2000) and has since been isolated from a wide
range of organisms, from myxomycetes to mammals, where
it is abundant in both serum and brain tissue (Bandoh et al.,
1999; Shan et al., 2008; Tsuda et al., 2006).
cPA has multiple biological functions including the reg-
ulation of cell proliferation and migration. cPA is a negative
regulator of cell division via its inhibition of mitogen-
activated protein kinase (MAPK) activity (Fischer et al., 1998;
Murakami-Murofushi et al., 1993, 2002). Moreover, cPA inhi-
bits the invasion of rat ascites hepatoma cells (MM1 calls) and
HT-1080 human ﬁbrosarcoma cells (Mukai et al., 2003;
Murakami-Murofushi et al., 2002).
cPA is abundant in the central nervous system where it
affects cell survival and neurite extension (Fujiwara et al.,
2003; Fujiwara, 2008; Gotoh et al., 2010; Hotta et al., 2006). In
addition, cPA exhibits neurotrophic effects in embryonic
hippocampal neurons (Fujiwara et al., 2003). In vivo, cPA
has a neuroprotective effect against both ischemia-induced
delayed neuronal death in the hippocampal CA1 region and
hypoxia-induced apoptosis in neuroblastoma Neuro2A cells
(Gotoh et al., 2010, 2012).
Cerebellar granule cell precursors (GCPs), which are the
most abundant neuronal precursors in the cerebellum, play
an important role in the development of the cerebellum
(Chizhikov and Millen, 2003; Hatten et al., 1982; Lander,
1987). Various extracellular factors regulate the proliferation
and differentiation of GCPs; Sonic hedgehog (Shh) and
insulin-like growth factor (IGF) are important for the prolif-
eration of GCPs (Bondy and Cheng, 2004; Calikoglu et al., 2001;
Dahmane and Ruiz i Altaba, 1999). Shh plays an important
role in the proliferation of GCPs as well as in the occurrence
of medulloblastoma, the most common cerebellar tumor
(Browd et al., 2006; Cordeiro et al., 2014; Dahmane and Ruiz
i Altaba, 1999; Roussel and Hatten, 2011; Vaillant and Monard,
2009). Several extracellular factors, such as the neuropeptide
pituitary adenylate cyclase-activating polypeptide (PACAP),
the cell adhesion molecule vitronectin, Wnt3, and the matri-
cellular protein, NOV, are known to be suppressors of Shh-
dependent cell proliferation in the cerebellum (Anne et al.,
2013; Le Dreau et al., 2009; Nicot et al., 2002; Niewiadomski
et al., 2013; Pons et al., 2001; Vaillant and Monard, 2009).
Although cPA is abundant in the central nervous system
(Bandoh et al., 1999; Shan et al., 2008), the effect of cPA on
GCPs in the cerebellum remains unknown.
Here, we investigated the role of cPA in the proliferation of
GCPs. Our results demonstrate that cPA suppresses Shh-
dependent cell proliferation and promotes the differentiation
of cerebellar granule cells. Furthermore, we revealed that
P2Y5 acts as a receptor for cPA in GCPs and plays an
important role in the regulation of the proliferation and
differentiation of GCPs.2. Results
2.1. The effect of cPA on the proliferation of GCPs
First, we investigated the effect of cPA on the proliferation of
cerebellar GCPs. To address this question, we cultured GCPs
derived from the cerebellum of postnatal day 6 (P6) mice, at
the height of proliferation in the cerebellum. Next, we
checked for glial cell incorporation in the culture. The
incorporation of glial cells was less than 3%, indicating that
this culture system was almost entirely composed of GCPs
and granule cells (data not shown).
To analyze the effect of cPA on the proliferation of GCPs,
we examined the number of cells in the S-phase using 2 h-
bromodeoxy uridine (BrdU)-labeling. cPA reduced the number
of BrdU positive cells, compared with vehicle treated cultures
(63% decreased) (Fig. 1A, B, and G). Next, we examined the
number of cells in the M-phase using the M-phase marker
phospho-histone H3 (Phh3). cPA signiﬁcantly reduced the
number of Phh3-positive cells by 46% (Fig. 1C, D, and H). To
investigate the effect of cPA on the efﬁciency of cell cycle exit,
GCPs were labeled with BrdU for 24 h and stained with BrdU
and Ki67, a marker of cell cycling. We then examined the
index of cell cycle exit (Ki67 ;BrdUþ/Ki67þ;BrdUþ). Com-
pared to the vehicle control, cPA increased the index from
1.46 to 2.43 (Fig. 1E, F, and I). Taken together, these results
show that cPA suppresses the proliferation of GCPs and
promotes cell cycle exit.
2.2. The effect of cPA on the differentiation of GCPs
As mentioned above, our results show that cPA suppresses
the proliferation of GCPs and promotes cell cycle exit,
suggesting that cPA may promote the differentiation of GCPs.
To examine whether cPA affects the differentiation of GCPs,
we used Tuj-1, a neuronal marker of cell differentiation, and
24 h BrdU labeling. cPA signiﬁcantly increased the number of
Tuj-1 and BrdU double positive cells by 1.4-fold (Fig. 2A, B,
and E). Moreover, the number of cells positive for BrdU and
NeuN, a marker of neuronal differentiation, was also
increased by cPA (1.7-fold increased) (Fig. 2C, D, and F). These
results are similar to those using Tuj-1.
Next, we veriﬁed whether cPA promotes the progression of
differentiation using TAG-1, a marker of early differentiation
in GCPs, combined with 24 h BrdU labeling. Treatment with
cPA did not signiﬁcantly affect the number of BrdU and TAG-1
double positive cells (Fig. 2G). This result suggests that cPA
does not affect the progression of the early differentiation of
GCPs. These results combined demonstrate that cPA sup-
presses cell proliferation and promotes the ﬁnal stages of
differentiation of GCPs.
2.3. The effect of cPA on Shh-and IGF-dependent cell
proliferation
The above experiments were performed in culture media
containing Shh. We next conﬁrmed whether the effect of cPA
on the proliferation of GCPs was Shh-dependent. To address
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of 24 h-labeled BrdU-positive cells with Shh or IGF-1. The
results showed that Shh treatment increased the number of
BrdU-positive cells, and the Shh-dependently increased
BrdU-positive cell number was reduced to baseline levels by
the cPA treatment (Fig. 3A), whereas cPA did not affect the
IGF-dependently increased BrdU positive cell numberFig. 1 – The effect of cPA on the proliferation of GCPs. In the prim
postnatal day 6 (P6), cPA (1 μM) (cPA) or 0.1% bovine serum album
were ﬁxed after 4 days in culture. (A, B, G) The effect of cPA on G
(BrdU) for 2 h. The GCPs were stained with anti-BrdU (green) and
(A, B). cPA signiﬁcantly reduced the number of BrdU-positive cell
vehicle control (G) (p¼6105, n¼3). (C, D, H) The effect of cPA
phosphohistone-H3 (Phh3) (green), a marker of M-phase, and DA
positive cells compared with the vehicle control (H) (p¼2.010
Ki67, a maker for cell cycling, and BrdU. The GCPs were labeled w
BrdU (red) and DAPI (blue) (E, F). The index of cell cycle exit was
Ki67-negative cells to the number of Ki67 and BrdU double-pos
exit, compared to the vehicle control (I) (p¼0.04, n¼3).(Fig. 3B). These results indicate that cPA suppresses the
Shh-dependent proliferation of GCPs, but not the IGF-
dependent proliferation.
Patched and Smoothened (Smo) play important roles in
the Shh-signaling pathway (Stanton and Peng, 2009; Vaillant
and Monard, 2009). Patched (Ptc) not only is a receptor for Shh
but also suppresses the activity of Smo. The binding of Shh toary cultured cells derived from the cerebellum of ICR mice at
in (BSA) (vehicle) was added at 1 day after plating. The cells
CPs in S-phase. GCPs were labeled with bromodeoxy uridine
4′6-diamidino-2-phenylindole dihydrochloride (DAPI) (blue)
s (normalized to the total number of cells) compared with the
on GCPs in M-phase. GCPs were stained with anti-
PI (blue) (C, D). cPA signiﬁcantly reduced the number of Phh3-
4, n¼3). (E, F, I) Analysis of the index of cell cycle exit using
ith BrdU for 24 h and stained with anti-Ki67 (green) and anti-
calculated from the ratio of the number of BrdU-positive and
itive cells. cPA signiﬁcantly increased the index of cell cycle
b r a i n r e s e a r c h 1 6 1 4 ( 2 0 1 5 ) 2 8 – 3 7 31Ptc disinhibits the activity of Smo, and thereby activates
downstream signaling of the pathway (Stanton and Peng,
2009; Vaillant and Monard, 2009). To examine which part of
the Shh-signaling pathway is affected by cPA, the effect of
cPA on the Smo agonist-dependent proliferation of GCPs was
investigated using 24 h-BrdU labeling. First, it was observed
that a Smo-agonist (4, 8, or 10 nM) increased the number of
BrdU-positive cells in a dose-dependent manner (Fig. 3C). At
8 nM of Smo-agonist, the Smo-agonist dependent prolifera-
tion of GCP was suppressed by cPA dose-dependently
(Fig. 3D). These results demonstrate that cPA suppresses the
Shh-signaling pathway downstream of Smo.
2.4. The role of P2Y5 in the suppression of GCP
proliferation by cPA
Next, we examined which receptor was responsible for
the cPA-induced suppression of GCP proliferation andFig. 2 – The effect of cPA on the differentiation of GCPs. cPA (1 μM
after plating. (A, B, E) The effect of cPA on the differentiation of GC
for 24 h and stained with anti-Tuj-1 (green), a neuronal marker o
cPA signiﬁcantly increased the efﬁciency of Tuj-1 positive differe
effect of cPA on the differentiation of GCPs using a NeuN antibod
marker of differentiation, anti-BrdU (red), and DAPI (blue) (C, D).
cPA signiﬁcantly increased the ratio (F); similar results were obt
effect of cPA on the early differentiation of GCPs using a TAG-1
early differentiation, and anti-BrdU. This result shows that cPA d
n¼3).promotion of differentiation. cPA is a lysophospholipid
that has a cyclic phosphate and is similar in structure to
LPA. LPA receptors have also been reported to bind cPA
(Murakami-Murofushi et al., 2002). As cPA speciﬁc recep-
tors have not yet been identiﬁed, we examined the expres-
sion level of different LPA receptors using reverse
transcribed-polymerase chain reaction (RT-PCR), and
found that only P2Y5 (LPA6) was highly expressed
(Fig. 4A). Therefore, we examined neurite retraction in
B103-p2y5 cells, a neuroblastoma cell line that stably
expresses P2Y5. These cells indeed exhibited neurite
retraction upon LPA and cPA stimulation. LPA was a more
potent activator than cPA; nonetheless, the results indi-
cated that cPA can function as a ligand for P2Y5 (Fig. 4B).
To verify whether cPA affects the proliferation and differ-
entiation of GCPs through P2Y5, we knocked down P2Y5
expression using small interfering RNAs (siRNA). The
efﬁciency of the P2Y5 knockdown was 32.4% at the mRNA) (cPA) or 0.1% BSA (vehicle) was added to the GCPs at 1 day
Ps using a Tuj-1 antibody. The GCPs were labeled with BrdU
f ﬁnal differentiation, anti-BrdU (red), and DAPI (blue) (A, B).
ntiation in the last 24 h (E) (p¼4.0104, n¼4). (C, D, F) The
y. The GCPs were stained with anti-NeuN (green), a neuronal
A comparison of the differentiation efﬁciency showed that
ained with the Tuj-1 antibody (p¼1.0104, n¼3). (G) The
antibody. GCPs were stained with anti-TAG-1, a marker of
id not affect the progress of early differentiation (G) (p¼0.48,
b r a i n r e s e a r c h 1 6 1 4 ( 2 0 1 5 ) 2 8 – 3 732level (data not shown). With the knockdown of P2Y5, the
suppression of cell proliferation by cPA was prevented to
some extent (Fig. 4C). Additionally, P2Y5 knockdown using
a second siRNA for P2Y5 showed a similar effect (data not
shown). These results demonstrate that P2Y5 is respon-
sible for at least part of the inhibitory growth effect on
GCPs, acting as a receptor for cPA.Fig. 3 – The mechanism by which cPA regulates cell proliferatio
agonist-dependent proliferation. (A) The effect of cPA on the Sh
Shh protein (50 ng/ml) in 0.1% BSA (Shh) or 0.1% BSA (control). Af
added to the culture with Shh, and the cells were labeled with
positive cells, the cPA treatment signiﬁcantly reduced the numb
Shh (control)) (p¼1.8108, n¼7). (B) The effect of cPA on IGF-1
protein (40 ng/ml) in 0.1% BSA (IGF) or 0.1% BSA (control). After
added to the culture with IGF-1. The results showed that cPA d
with IGF-1 (cPA and vehicle) (p¼0.074, n¼6). (C) The effect of Smo
8, or 10 nM) and then labeled with BrdU for 24 h. Smo-agonist i
(Smo-agonist 0 nM/4 nM), p¼3.7108 (0 nM/8 nM), p¼2.910
dependent proliferation of GPCs. GPCs were cultured with Smo-a
added and the GPCs were labeled with BrdU for 24 h. The resul
number was reduced by cPA (p¼0.02 (0 lM/5 lM), p¼0.04 (5 lM/3. Discussion
In this study, we investigated the effect of cPA on developing
cerebellar GCPs. We examined primary cultures derived from
mouse P6 cerebellar GCPs. Our results reveal that cPA sup-
presses Shh-dependent cell proliferation and promotes then. We investigated the effect of cPA on Shh-, IGF-, and Smo-
h-dependent proliferation of GCPs. GPCs were cultured with
ter 1-day of culture, cPA (1 μM) (cPA) or 0.1% BSA (vehicle) was
BrdU for 24 h. While Shh increased the number of BrdU-
er of BrdU-positive cells back to baseline levels (i.e., without
-dependent proliferation. GPCs were cultured with IGF-1
1-day of culture, cPA (1 μM) (cPA) or 0.1% BSA (vehicle) was
id not signiﬁcantly affect the number of BrdU-positive cells
-agonist on GCPs. GPCs were cultured with Smo-agonist (0, 4,
ncreased the number of BrdU-positive cells. (p¼2.3109
14 (0 nM/10 nM)) (D) The effect of cPA on the Smo-agonist-
gonist (8 nM). After 1-day of culture, cPA (0, 5, or 10 lM) was
ts showed that the Smo-agonist-dependent increase in cell
10 lM)).
Fig. 4 – The characterization of cPA receptor candidates in GCPs. (A) Quantiﬁcation of the mRNA levels of the cPA receptor
candidates in GCPs. Total RNA was isolated from 4-day cultured GCPs. Each LPA receptor mRNA level was relatively quantiﬁed
using the ΔΔCt method for real-time reverse transcribed-polymerase chain reaction (RT-PCR). The amount of LPA1 was
regarded as 1, and the amount of each receptor candidate for cPA was normalized to LPA1. (B) Neurite retraction of B103-p2y5
cells induced by LPA and cPA. B103-p2y5 cells were serum-starved and stimulated with various concentrations of LPA 18:1,
cPA 16:0 and cPA 18:1 for 10 min. The cells were then ﬁxed. The ratio of responsive cells was quantiﬁed as the number of
rounded cells over the total number of cells. The ratio of responsive cells was expressed as the mean7standard error. The
data were analyzed using a Student's t-test (*po0.05 and **po0.01 vs. vehicle-treated group for LPA 18:1, cPA 18:1, #po0.05
and ##po0.01 vs. vehicle-treated group for cPA 16:0). (C) Knockdown of the P2Y5 receptor. GCPs were transfected with small
interfering RNAs (siRNA) (si-P2Y5) or negative-control siRNA at 1-day after plating and cultured with or without cPA (2.5 μM)
for 2 additional days. The GCPs were labeled with BrdU for 24 h before ﬁxation. That results show that the number of BrdU-
positive cells that was reduced by cPA was recovered by si-P2Y5 treatment (p¼0.004).
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Smo agonist suggest that cPA suppresses the Shh signaling
pathway downstream of Smo. Moreover, we propose that the
cPA receptor responsible for the suppression of GCP prolif-
eration is P2Y5 (LPA6).
3.1. The role of cPA in cerebellar development
cPA suppresses the Shh-dependent cell proliferation of GCPs.
The effect of cPA appears to be similar to that of PACAP and
NOV, both known suppressors of the Shh-dependent cell
proliferation in cerebellar GCPs (Le Dreau et al., 2009; Nicot
et al., 2002). We also detected the presence of autotaxin
mRNA, a synthetic enzyme of cPA, in GCPs (data not shown).
These results suggest that cPA is secreted from GCPs and
diffuses throughout the external granular layer (EGL) in vivo.
GCPs proliferate in the EGL, exit the cell cycle, and then
initiate their differentiation into granule cells in the inner EGL
(iEGL) (Alder et al., 1996; Lee et al., 2011). Our results suggest
that cPA secreted from GCPs diffuses throughout the EGL; cPAceases the proliferation of GCPs and initiates the differentia-
tion of GCPs in the iEGL during the development of the
cerebellum (Behesti and Marino, 2009; Hatten et al., 1982;
Miale and Sidman, 1961; Wey et al., 2010).
3.2. The mechanism underlying cPA-mediated
suppression of Shh-dependent cell proliferation
We analyzed the mechanism by which cPA suppresses GCP
proliferation. In our experiments, cPA did not suppress the
IGF-dependent cell proliferation of GCPs, but speciﬁcally
suppressed Shh-dependent cell proliferation. The signaling
pathway of Shh-dependent proliferation is as follows. In the
absence of Shh, Ptc, a receptor for Shh, suppresses the
activity of Smo. However, the binding of Shh to Ptc inhibits
the suppression of Smo, thereby activating the Shh-signaling
pathway through Smo (Stanton and Peng, 2009; Vaillant and
Monard, 2009). Shh signaling activates the transcription of N-
myc. Subsequently, N-myc up-regulates the expression of
cyclin D and promotes cell proliferation (Browd et al., 2006).
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results in the degradation of N-myc (Browd et al., 2006). In
this way, each signaling pathway (i.e., Shh and IGF) is
different. Our results indicate that cPA speciﬁcally affects
the Shh-signaling pathway as it suppressed the proliferation
of GCPs induced by a Smo agonist. Taken together, our results
support the notion that cPA suppresses the downstream
pathway of Smo in GCPs.
3.3. cPA receptor candidates in GCPs
We identiﬁed a candidate receptor through which cPA reg-
ulates the proliferation and differentiation of GCPs. cPA and
LPA are lysophospholipids that are similar in structure, and
the same enzyme is responsible for their synthesis. So far,
several receptors have been identiﬁed for LPA, and LPA1-5
have also been shown to bind cPA (Baker et al., 2006; Fujiwara
et al., 2005; Fujiwara, 2008). Therefore, we examined which
LPA receptors were expressed in GCPs. Our results revealed
that the mRNA level of P2Y5 (LPA6) was the highest among
the LPA receptors. P2Y5 belongs to the non-Edg subfamily of
the LPA receptor family (Ishii et al., 2009). Human P2Y5 is a
G-protein coupled receptor (GPCR) encoded within an intron
of the retinoblastoma (Rb) gene (Herzog et al., 1996) and is
recognized as a LPA receptor family member because human
P2Y9/GPR23 (LPA4) is closely related to human P2Y5 (Janssens
et al., 1997). It has been reported that mutations in the P2Y5
gene cause woolly hair/hypotrichosis (Pasternack et al., 2008),
and it is suggested that P2Y5 regulates the development of
follicle cells and hair growth. Our results show that P2Y5 is a
functional receptor for cPA and is responsible for cPA signal-
ing in GCPs. This is the ﬁrst report identifying P2Y5 as a
receptor for cPA in GCPs.
3.4. The mechanism underlying the P2Y5-dependent
suppression of GCP proliferation by cPA
Our results suggest that P2Y5-mediated signaling is respon-
sible for the suppression of GCP proliferation by cPA. A
number of pathways through P2Y5 have been reported (Lee
et al., 2009; Pasternack et al., 2008; Yanagida et al., 2009). P2Y5
is known to couple to G12/13 protein signaling (Ishii et al.,
2009). LPA activates the G13-Rho signaling pathway in P2Y5-
expressing rat neuroblastoma B103 cells (Yanagida et al.,
2009). In addition, P2Y5 reduces cell adhesion in the intestine
by LPA and this reduction is mediated by G12/13 (Lee et al.,
2009). One study using P2Y5-overexpression in CHO cells has
suggested that P2Y5 is coupled to Gsα, resulting in an
increase in cAMP levels. Thus far, however, a function for
P2Y5 stimulated by cPA in the nervous system has yet to be
reported.
The complete mechanism underlying the suppression of
GCP cell proliferation is not yet clear. We propose two
possibilities: one being that protein kinase A (PKA) phosphor-
ylates Gli, a component of the Shh-signaling pathway, and
thereby induces the degradation of Gli through the proteaso-
mal pathway (Jiang, 2006; Vaillant and Monard, 2009). The
activity of PKA is known to be upregulated by Gsα-coupled
receptors such as the PACAP receptor via cAMP (Miyamoto
et al., 1994). As mentioned above, P2Y5 could potentially becoupled to Gsα. The other possibility is that P2Y5 couples with
G12/13 to activate PI-3 kinase and thus inactivate GSK3β, such
as occurs with NOV. However, as mentioned above, cPA does
not inhibit the IGF-dependent proliferation of GCPs, which
makes this possibility less likely.
The cell proliferative signaling caused by Shh is main-
tained by a balance between Shh and its various suppressors
(Roussel and Hatten, 2011). An unbalance causes aberrations
in cerebellar formation (Behesti and Marino, 2009; Roussel
and Hatten, 2011). For example, the overexpression of Shh
induces tumorigenesis and medulloblastoma, a childhood
cancer (Behesti and Marino, 2009; Dahmane and Ruiz i
Altaba, 1999). In this study, we revealed that cPA suppresses
the Shh-dependent cell proliferation of GCPs and suggest that
cPA acts in concert with PACAP and NOV to suppress this
proliferation. These results could potentially contribute to the
development of novel treatments for medulloblastoma.
3.5. Conclusion
We revealed that cPA suppresses the proliferation of GCPs
while promoting the ﬁnal stage of GCP differentiation.
Furthermore, we found that cPA speciﬁcally suppresses the
proliferation induced by Shh but not IGF signaling and that
P2Y5 (LPA6) mediates this suppression effect of cPA. In
conclusion, we have demonstrated that cPA suppresses the
Shh-dependent proliferation of GCPs through P2Y5.4. Experimental procedures
4.1. Animals
Pregnant ICR mice were obtained from Charles River labora-
tories, Japan (Yokohama, Japan). The mice were maintained
at a constant temperature (22 1C) with a 12 h light–dark cycle
(8:00–20:00). Postnatal day-animal care was approved by the
Institutional Animal Care and Use Committee of Ochanomizu
University (animal study protocols 12010, 13002, and 14006)
and followed the guidelines of the Ministry of Education,
Science and Culture in Japan.
4.2. Pharmacological agents
cPA 16:0 was chemically synthesized as previously described
(Kobayashi et al., 1993). Bovine serum albumin (BSA; fraction
V, fatty acid free) was purchased from Sigma-Aldrich (St.
Louis, MO). Smo agonist (Sonic Hh Ag 1.5) was purchased
from Cellagen Technology (San Diego, CA). DNase I was
purchased from Roche Diagnostics (Bazel, Switzerland).
4.3. Cell culture
The culture of GCPs was performed using a modiﬁcation of
the procedure described by Weber and Schachner (1984).
Postnatal day-6 wild-type ICR mouse cerebella were washed
in Hanks balanced salt solution (HBSS: 136 mM NaCl, 5.36 mM
KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 1 mg/ml glucose,
4.17 mM NaHCO3) and digested using 1% trypsin and
DNase I (0.5 mg/ml) in HBSS for 13 min at room temperature.
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I in HBSS, dispersed by pipetting, and passed through a nylon
net with a mesh size of 70 mm. The dispersed cells were
resuspended in serum-free media (Neurobasal Medium (Life
technologies, Carlsbad, CA), supplemented with 500 mM L-
glutamine, 2% B-27 Supplement (Life technologies), 20 mM
KCl, 50 unit/ml penicillin and 50 ml/ml streptomycin) with
50 ng/ml Shh protein or the indicated concentration of Smo
agonist. The cell density was adjusted to 4.0–6.0105 cells/
ml. The cell suspensions were plated on poly-L-lysine (PLL)-
coated 24-well plates and cultured at 5% CO2 and 37 1C. After
1-day of culture, the indicated concentration of cPA or 0.1%
BSA was added to the culture media. For immunostaining of
the cells, hydrophilic treated glass cover slips were added to
the 24-well plates prior to the PLL treatment. During the
culture period, one-half of the volume of culture media was
exchanged with fresh media at 2 and 3 days after plating, and
the cells were ﬁxed at 4 days after plating. To label the
cultured cells with BrdU, BrdU (20 mM) was added to the
culture media at 24 h or 2 h before ﬁxation.
4.4. Immunoﬂuorescence staining
Immunostaining of the cultured cells was performed as
follows. The 3-day cultured cells were washed in phosphate
buffered saline (PBS: 8 g/l NaCl, 2.9 g/l Na2HPO4/12H2O, 0.2 g/l
KCl, 0.2 g/l KH2PO4); the cells were then ﬁxed using 4%
paraformaldehyde (PFA) in 0.2 M PBS for 20 min at room
temperature. The ﬁxed cells were washed with PBS and then
blocked with Tris-buffered saline (TBS)þþþþ (10% calf serum,
3% BSA, 130 nM glycine, 0.4% Triton-X100; in TBS). The cells
were incubated with primary antibody overnight and then
with secondary antibodies for 1 h in dark (Table 1). To stain
with anti-BrdU and anti-Ki67 antibodies, the cells were boiled
in 10 mM citrate buffer (pH 6.0) prior to blocking. Following
antibody staining, the cells were stained with 0.5 mg/ml 40,6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Roche
Diagnostics) in PBS. Images were captured using a micro-
scope (FSX100, Olympus, Tokyo, Japan).
4.5. Introduction of siRNA against P2Y5 in cultured GCPs
To knockdown P2Y5, cultured GCPs were transfected with a
siRNA (Stealth RNAiTM siRNA, Life Technologies) against P2Y5Table 1 – Kind of the antibody which it used in this experime
Primary antibodies (dilution)
Anti-GFAP (1:200)
Anti-BrdU (1:500)
Anti-Ki67 (1:200)
Anti-TAG1 (1:200)
Anti-Tuj1 (1:200)
Secondary antibodies (dilution)
Alexa Fluor 488 goat anti-mouse IgG (1:200)
Alexa Fluor 488 goat anti-rabbit IgG (1:200)
Alexa Fluor 488 goat anti-mouse IgM (1:200)
Alexa Fluor 568 goat anti-mouse IgG (1:200)
Alexa Fluor 568 goat anti-rabbit IgG (1:200)
Alexa Fluor 568 goat anti-mouse IgM (1:200)or a control siRNA (Negative Control Hi GC, Med GC, or LoGC).
To transfect the siRNAs, a mixture of 0.5 μl Lipofectamine
2000 (Life Technologies) and 1.5 μl of each siRNA (20 μM) in
100 μl of OptiMEM (Life Technologies) was added into each
well of a 24-well plate at 1 day after plating, and incubated for
5 h. The GCPs were cultured with or without 2.5 μM cPA for 2
additional days.
4.6. Real-time RT-PCR
To examine the expression level of each LPA receptor, total
RNA was extracted from the cultured GCPs. The total RNA
was reverse-transcribed and subjected to real-time RT-PCR
using Platinum SYBR Green qPCR SuperMix-UGD (Life Tech-
nologies). mRNA levels were quantiﬁed using an ABI 7300
real-time PCR machine (Life Technologies). Gene-speciﬁc
primer sets were used as previously reported (Gotoh et al.,
2012). To conﬁrm the efﬁciency of knockdown, the following
primer pair set was used: 50-CCAGTGCCCTTATGACGACT-30
(F) and 50-CACAGCAATGCAAACGATCT-30 (R). The data were
analyzed using the delta Ct method. The expression level of
each LPA receptor was normalized to β-actin expression.
4.7. Analysis of neurite retraction
B103-p2y5 cells, rat neuroblastoma cells that stably express
P2Y5, were kindly provided by Prof. Takao Shimizu (Univer-
sity of Tokyo, Tokyo, Japan) and maintained as described
previously (Yanagida et al., 2009). The morphological changes
of B103-p2y5 cells induced by LPA 18:1, cPA 16:0 or cPA 18:1
were measured as follows. Brieﬂy, the cells were seeded at
1104 cells/well in a 24-well plate and cultured overnight.
Then, the cells were serum-starved for 8 h. After serum-
starvation, the cells were stimulated with various concentra-
tions of the indicated compounds for 10 min, and then ﬁxed
with 2% PFA. To quantify the ratio of responsive cells, the
number of rounded cells and total cells were counted (Lee
et al., 2007).
4.8. Statistical analysis
At least three independent experiments were performed, and
the data were analyzed using a Student's t-test. The resultsnt.
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values o0.05 were considered signiﬁcant.
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